Dual-acting EUFLEXXA: Robust study design. Statistically significant results.2,3
The efficacy and safety of EUFLEXXA was studied across 3 robust clinical trials2,3
Compared to Synvisc, EUFLEXXA delivered:
Primary Endpoint
![study-1__analysis-data-desktop](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-1__analysis-data-desktop.png)
![study-1__primary-mobile](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-1__primary-mobile.png)
![takeaway__icon-2-3](https://hcp.euflexxa.com/wp-content/uploads/2023/10/takeaway__icon-2-3.png)
†Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).
Secondary Endpoints
![study-1__secondary-data-desktop](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-1__secondary-data-desktop.png)
![study-1__secondary-mobile](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-1__secondary-mobile.png)
Most common adverse events (AEs) in 12-week pivotal trial vs Synvisc2,3
![](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-1__adverse-effects-e1697516161107.png)
Compared to the control group, EUFLEXXA delivered:
Primary Endpoint
![~1/2](https://hcp.euflexxa.com/wp-content/uploads/2023/12/1-2.png)
![~1/2](https://hcp.euflexxa.com/wp-content/uploads/2023/12/1-2.png)
of EUFLEXXA patients were PAIN-FREE at 6 months2,4
Pain-free (<20 mm) was determined at week 26 using the 100 mm VAS based on the 50-foot walk test.
Secondary Endpoint
![flex-trial__secondary-data-desktop](https://hcp.euflexxa.com/wp-content/uploads/2024/01/flex-trial__secondary-data-desktop.png)
![study-2__secondary-mobile](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-2__secondary-mobile.png)
Most common AEs in 26-week FLEXX trial2
the treatment groups
![](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-2__adverse-effects.png)
Primary Endpoint
![flex-extension-trial__primary-data-desktop](https://hcp.euflexxa.com/wp-content/uploads/2024/01/flex-extension-trial__primary-data-desktop.png)
![study-3__primary-mobile](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-3__primary-mobile.png)
Post-hoc analyses are limited by their post-hoc design and thus prone to increased bias. Such analyses are exploratory and should not be used to infer causative relationships between variables.
Most common AEs in 26-week FLEXX Extension trial2
among the treatment groups
![](https://hcp.euflexxa.com/wp-content/uploads/2023/10/study-3__adverse-effects.png)
§KL=Kellgren-Lawrence grading scale; KL grades are determined radiographically. KL-2 (n=235), KL-3 (n=353).
¶All numbers rounded to the nearest whole number.
- Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
- EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
- Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.
- Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9.
- Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19(10):1169-1175.